|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAB2B |
Gene summary for RAB2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAB2B | Gene ID | 84932 |
| Gene name | RAB2B, member RAS oncogene family | |
| Gene Alias | RAB2B | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B4DUD4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84932 | RAB2B | LZE4T | Human | Esophagus | ESCC | 7.41e-10 | 3.18e-01 | 0.0811 |
| 84932 | RAB2B | LZE20T | Human | Esophagus | ESCC | 2.71e-04 | 1.07e-01 | 0.0662 |
| 84932 | RAB2B | LZE24T | Human | Esophagus | ESCC | 2.71e-16 | 1.12e-01 | 0.0596 |
| 84932 | RAB2B | LZE6T | Human | Esophagus | ESCC | 1.82e-02 | 5.98e-02 | 0.0845 |
| 84932 | RAB2B | P1T-E | Human | Esophagus | ESCC | 2.40e-02 | 6.61e-02 | 0.0875 |
| 84932 | RAB2B | P2T-E | Human | Esophagus | ESCC | 1.33e-10 | 8.88e-02 | 0.1177 |
| 84932 | RAB2B | P4T-E | Human | Esophagus | ESCC | 1.99e-06 | 1.04e-01 | 0.1323 |
| 84932 | RAB2B | P5T-E | Human | Esophagus | ESCC | 3.11e-07 | 7.02e-02 | 0.1327 |
| 84932 | RAB2B | P8T-E | Human | Esophagus | ESCC | 2.63e-12 | 2.02e-01 | 0.0889 |
| 84932 | RAB2B | P9T-E | Human | Esophagus | ESCC | 1.12e-09 | 4.93e-02 | 0.1131 |
| 84932 | RAB2B | P10T-E | Human | Esophagus | ESCC | 8.23e-14 | 2.11e-01 | 0.116 |
| 84932 | RAB2B | P11T-E | Human | Esophagus | ESCC | 1.87e-11 | 2.83e-01 | 0.1426 |
| 84932 | RAB2B | P12T-E | Human | Esophagus | ESCC | 1.14e-15 | 3.93e-01 | 0.1122 |
| 84932 | RAB2B | P15T-E | Human | Esophagus | ESCC | 6.19e-15 | 2.72e-01 | 0.1149 |
| 84932 | RAB2B | P16T-E | Human | Esophagus | ESCC | 5.90e-14 | 1.16e-01 | 0.1153 |
| 84932 | RAB2B | P21T-E | Human | Esophagus | ESCC | 7.06e-05 | 6.94e-02 | 0.1617 |
| 84932 | RAB2B | P22T-E | Human | Esophagus | ESCC | 2.59e-06 | 6.11e-02 | 0.1236 |
| 84932 | RAB2B | P23T-E | Human | Esophagus | ESCC | 2.07e-11 | 1.70e-01 | 0.108 |
| 84932 | RAB2B | P26T-E | Human | Esophagus | ESCC | 9.38e-09 | 2.20e-01 | 0.1276 |
| 84932 | RAB2B | P27T-E | Human | Esophagus | ESCC | 3.55e-20 | 3.23e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAB2B | SNV | Missense_Mutation | c.304N>C | p.Glu102Gln | p.E102Q | Q8WUD1 | protein_coding | tolerated(0.15) | benign(0.035) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| RAB2B | SNV | Missense_Mutation | novel | c.537N>G | p.His179Gln | p.H179Q | Q8WUD1 | protein_coding | tolerated(0.14) | benign(0) | TCGA-VS-A8EJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| RAB2B | SNV | Missense_Mutation | novel | c.38N>C | p.Gly13Ala | p.G13A | Q8WUD1 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-VS-A9U7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RAB2B | SNV | Missense_Mutation | novel | c.91T>G | p.Phe31Val | p.F31V | Q8WUD1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RAB2B | SNV | Missense_Mutation | novel | c.441A>C | p.Glu147Asp | p.E147D | Q8WUD1 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RAB2B | SNV | Missense_Mutation | novel | c.151G>A | p.Asp51Asn | p.D51N | Q8WUD1 | protein_coding | tolerated(0.44) | benign(0.029) | TCGA-DD-AAE6-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| RAB2B | SNV | Missense_Mutation | c.503N>C | p.Tyr168Ser | p.Y168S | Q8WUD1 | protein_coding | deleterious(0.02) | probably_damaging(0.947) | TCGA-78-7536-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
| RAB2B | SNV | Missense_Mutation | c.377G>T | p.Arg126Leu | p.R126L | Q8WUD1 | protein_coding | deleterious(0.02) | benign(0.017) | TCGA-85-6561-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD | |
| RAB2B | SNV | Missense_Mutation | novel | c.205C>A | p.Arg69Ser | p.R69S | Q8WUD1 | protein_coding | deleterious(0.01) | probably_damaging(0.94) | TCGA-85-6561-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD |
| RAB2B | SNV | Missense_Mutation | novel | c.319N>T | p.His107Tyr | p.H107Y | Q8WUD1 | protein_coding | tolerated(0.58) | benign(0.066) | TCGA-BA-5151-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |